Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 12241-12250 Newer>

The Motley Fool February 6, 2006 Rich Smith	Foolish Forecast: Cracking Coke Open Whatever happens tomorrow with the net margin under GAAP, it's more important for investors to watch Coca-Cola's free cash flow, which usually exceeds accounting profits by a considerable amount.
The Motley Fool February 6, 2006 Rich Smith	Foolish Forecast: Cheesecake, Anyone? Cheesecake Factory's meals may not be overpriced, but its stock sure is looking that way.
The Motley Fool February 6, 2006	Learn About Lock-Up Periods IPOs have some interesting quirks investors should know about.
The Motley Fool February 6, 2006 Rich Smith	Foolish Forecast: Chewing Over Wrigley For investors, watching Wrigley's margin movement is like chewing on a stick of gum. It gives you something to do with your time, but doesn't really accomplish much.
The Motley Fool February 6, 2006 Rich Smith	Foolish Forecast: Under Armour Undresses Under Armour's short history doesn't tell investors much more than that gross margins are strengthening -- a strength that hasn't yet dropped to the bottom line.
The Motley Fool February 6, 2006 Rick Aristotle Munarriz	4 Stocks That Took a Hike Companies with growing yields can make you rich -- in more ways than the obvious. Here's a closer look at four of the companies that inched their payouts higher last week: Sabre Holdings... Aflac... Brookfield Homes... Pitney Bowes...
BusinessWeek February 13, 2006 Gene G. Marcial	Watch It, Counterfeiters A beneficiary in the fight against counterfeiting is Document Security Systems, whose shares have shot up.
BusinessWeek February 13, 2006 Gene G. Marcial	Apoplexy: Renovis Takes Aim Renovis, a young biopharma developing treatments for pain, trauma, and stroke, could be joining the big leagues.
BusinessWeek February 13, 2006 Gene G. Marcial	YM Biosciences' Cancer Drugs Are Working Tiny biotech, YM Biosciences, trading on the Amex, may have a winner: Tesmilifene for metastatic breast cancer.
The Motley Fool February 3, 2006 Andy Cross	Comcast Delivers the Top Line: Fool by Numbers The cable television provider released fourth-quarter 2005 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights...
<Older 12241-12250 Newer> Return to current articles.